2021 Conference

September 11-12

81Days 07Hours 27Minutes 41Seconds

TurtleWear Giving Campaign

Updated: May 18, 2021: COVID-19 Vaccination within the GBS, CIDP, and Variant Community

GBS/CIDP Foundation of Canada will actively post the latest COVID-19 vaccination information that pertains to our patient population, provided by experts in the field, and is reviewed by our Medical Advisory Board as accurate. Please consider your information sources to avoid any confusion and continue to visit our website www.gbscidp.ca for the latest relevant information from experts.
The Foundation continues to advise you to have a conversation with your treating specialist or your healthcare provider about the benefits vs. risks of vaccination based on your individual health status.

GBS/CIDP Foundation of Canada COVID-19 Vaccination statement – Updated May 18, 2021

The Canadian Medical Advisory Board of GBS/CIDP Foundation of Canada has just released the following COVID-19 vaccination guidelines for Canadian patients with GBS, CIDP, and MMN.

COVID-19 Vaccination Guidelines

  1. We recommend vaccination for all GBS, CIDP, and MMN patients as soon as possible as per their provincial authorities, unless a patient has developed their disease within 6 weeks of any prior vaccine.
  2. We do not recommend any one vaccine in particular. Patients should follow Health Canada and the National Advisory Committee on Immunization (NACI) recommendations.
  3. We do not recommend a specific timing of the vaccine with plasmapheresis treatments or with IVIG/SCIG infusions. It can be done at any time during their cycle.
  4. For vaccines requiring 2 doses, we recommend receiving the second dose within 28 days of the first one, if possible as per each provincial authority.
While data specific to the safety and efficacy of the currently available vaccines in people with autoimmune disease and who take immunosuppressant therapies is not currently available, we agree that the benefits of COVID-19 immunization outweigh any theoretical risks of immunization. 
As the immune response to COVID-19 immunization is unknown for those taking immunosuppressant or immunomodulating therapy, patients with neuroimmunological disease who receive the COVID-19 vaccine should continue to closely follow public health recommendations including social distancing, regular hand washing/disinfection and avoiding public transport. 


Added June 1, 2021 – Vaccine Injury Support Program – Link to >> Public Health Agency of Canada <<

The Centers for Disease Control and Prevention (CDC), has published

 >> Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC. <<

The statements relevant to patients receiving antibody therapies, such as an IG product, are found in the sub-section titled:

Persons who previously received passive antibody therapy, and include:

For persons receiving antibody therapies not specific to COVID-19 treatment (e.g., intravenous immunoglobulin, RhoGAM), administration of COVID-19 vaccines either simultaneously with or at any interval before or after receipt of an antibody-containing product is unlikely to substantially impair development of a protective antibody response. Thus, there is no recommended minimum interval between antibody therapies not specific to COVID-19 treatment and COVID-19 vaccination. ¹

1. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. CDC Link >> Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines <<. Last updated on March 5, 2021.

Posted Oct 29, 2020

Vaccination Related Issues in Immune Neuropathies

presented by Dr. Hans Katzberg,

(Medical Advisory Board, Prosserman Neuromuscular Clinic)

Watch Dr. Katzberg’s Video

Health Canada Updates

Health Canada – Pfizer-BioNTech COVID-19 vaccine: What you should know

Health Canada – Moderna COVID-19 vaccine: What you should know

Health Canada – AstraZeneca COVID-19 vaccine: What you should know

Health Canada – Jannsen COVID-19 vaccine: What you should know

Our Vision:

Every person affected by GBS, CIDP, or variants such as MMN, will have access to early and accurate diagnosis, expert interdisciplinary treatment and support, and through continued research, a cure will be developed.

Our Mission:

To engage in advocacy, including treatment access,(at the federal, provincial and grassroots levels) to improve the quality of life for individuals and families affected by GBS, CIDP, or variants such as MMN.

The GBS/CIDP Foundation of Canada is a registered Canadian charity founded in 2003. Our foundation continues its long history of connecting patients and their families with caring and dedicated volunteers who have been affected by GBSCIDP, and variants, such as MMN. It is our hope that no patient or family will have to go through any of these disorders alone.

Along with this patient-to-patient support, the foundation has proudly established a National Medical Advisory Board of 18 Neurologists trained in the diagnosis and treatment of our disorders.

We are committed to building relationships with experts in rehabilitation and support disciplines who understand the challenges facing our patients during and after recovery. Our latest goal is to create a council of professionals that will help guide and educate patients on best practices in their disciplines.

We support Canadian research that will improve the diagnosis, treatment, and rehabilitation of patients affected by GBSCIDP, and variants. Our ultimate goal is to help pave the way to a cure. We proudly support IGOS and the Canadian contribution to the International GBS Outcome Study.

We are Challenging you to join us for the GBS /CIDP/MMN Awareness Challenge 2020!

This year our Challenge is simply to do an activity or simply “Strike a pose” holding your printed sign. Video your activity or take a pic, Challenge 2 more people, and Share the Challenge.

Send your Photo or Video to


Platinum Sponsor

Platinum Sponsor

Platinum Sponsor



Contact Us...

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt